# Central Nervous System (CNS) Agents: Narcolepsy

## Length of Authorizations

365 Days

## Prior Authorization Criteria

Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:

-   Allergy to medications not requiring prior approval
-   Contraindications to or drug interaction with medications not requiring prior approval
-   History of unacceptable/toxic side effects to medications not requiring prior approval

## Non-Preferred Medication

-   For non‐preferred drugs without medication specific criteria, there must have been an inadequate clinical response to preferred alternatives, including a trial of no less than 30 days each of at least two preferred products

## Prior Authorization Criteria

-   Sunosi (soriamfetol)
    -   Diagnosis of narcolepsy with excessive daytime sleepiness or obstructive sleep apnea with excessive daytime sleepiness **AND**
    -   An inadequate response to or inability to tolerate a 30-day course of treatment with modafinil or armodafinil **AND**
    -   An inadequate response to or inability to tolerate a 30-day course of treatment with a preferred methylphenidate or amphetamine product
-   Wakix (pitolisant), Xyrem (sodium oxybate)
    -   Diagnosis of narcolepsy with excessive daytime sleepiness **AND**
    -   An inadequate response to or inability to tolerate a 30‐day course of treatment with modafinil or armodafinil **AND**
    -   An inadequate response to or inability to tolerate a 30‐day course of treatment with a preferred methylphenidate or amphetamine product **OR**
    -   Diagnosis of narcolepsy with cataplexy
-   Xywav (calcium, magnesium, potassium & sodium oxybates)
    -   Diagnosis of narcolepsy with excessive daytime sleepiness **AND**
    -   An inadequate response to or inability to tolerate a 30‐day course of treatment with modafinil or armodafinil **AND**
    -   An inadequate response to or inability to tolerate a 30‐day course of treatment with a preferred methylphenidate or amphetamine product **AND**
    -   Sodium restriction with documented adherence to sodium restricted diet **OR**
    -   Diagnosis of narcolepsy with cataplexy **AND**
    -   Sodium restriction with documented adherence to sodium restricted diet

## Reauthorization Criteria

Attestation that the patient’s condition has improved while taking the requested medication

## Narcolepsy

Central Nervous System (CNS) Agents: Narcolepsy

| PREFERRED                     | NON-PREFERRED |
|-------------------------------|---------------|
| Amphetamine/Dextroamphetamine | Sunosi        |
| Armodafinil                   | Wakix         |
| Dextroamphetamine ER          | Xyrem         |
| Methylphenidate ER            | Xywav         |
| Methylphenidate Tab           |               |
| Modafinil                     |               |

### Link to Criteria

[Central Nervous System (CNS) Agents: Narcolepsy](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220415_UPDL_Criteria_FINAL_.pdf#page=38)
